ArticleCancer cell2020
Cytotoxic CD4
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- CD4Cancer biology & medicine · 2026Review
- Integrating Single-Cell Transcriptome-Wide Mendelian Randomization and Differentially Expressed Gene Analyses to Prioritize Dynamic Immune-Related Drug Targets for Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer: A Multidisciplinary Bioinformatics Approach.Biomedicines · 2025Article
- Role of CD4Journal of translational medicine · 2025Review
- Brain microenvironment orchestrates highly aggressive tumor variants: current trends and therapeutic approaches.Frontiers in aging neuroscience · 2025Review
- Review
- Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer.iScience · 2024Article
- Article
- Role of T cells in cancer immunotherapy: Opportunities and challenges.Cancer pathogenesis and therapy · 2023Review
- Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA.Frontiers in immunology · 2023Article
- Mapping the tumor microenvironment in clear cell renal carcinoma by single-cell transcriptome analysis.Frontiers in genetics · 2023Article
- HYAL3 as a potential novel marker of BLCA patient prognosis.BMC genomic data · 2022Article
- Heterogeneity and clonality of kidney-infiltrating T cells in murine lupus nephritis.JCI insight · 2022Article
- CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.Frontiers in immunology · 2022Article
- Mapping the tumor microenvironment in bladder cancer and exploring the prognostic genes by single-cell RNA sequencing.Frontiers in oncology · 2022Article
- Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration.Disease markers · 2022Article
- MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer.Frontiers in cell and developmental biology · 2022Article
- Review
- Article
- Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.Frontiers in immunology · 2021Article
Corrections and comments
- Comment onIntratumoral CD42020
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.